In an effort to define the antigenic mechanism that contributes to beneficial therapeutic outcome in patients with polycythemia vera (PV), we screened a human testis cDNA library with serological cloning derived from sera of three PV patients who had undergone therapeutic-induced remission. As a result, we identified a novel antigen, MPD5, which belongs to the group of cryptic antigens with unconventional genomic intron/exon structure. Moreover, MPD5 elicited IgG antibody responses in a subset of PV patients who had benefited from a variety of therapies-including IFN-a, Hydroxyurea, Imatinib mesylate, Anagrelide, and phlebotomy-but not in untreated PV patients or healthy donors, suggesting that MPD5 is a PV-associated, therapy-related antigen. In the granulocytes of PV patients who are responsive to therapy, up regulated MPD5 expression may serve to enhance immune responses. These findings provide new insight into the mechanism underlying regulation of the self-antigen repertoire that elicits anti-tumor immune responses in patients with myeloproliferative diseases, indicating the potential of these self-antigens as targets of novel immunotherapy.
In an effort to define the antigenic mechanism that contributes to beneficial therapeutic outcome in patients with polycythemia vera (PV), we screened a human testis cDNA library with serological cloning derived from sera of three PV patients who had undergone therapeutic-induced remission. As a result, we identified a novel antigen, MPD5, which belongs to the group of cryptic antigens with unconventional genomic intron/exon structure. Moreover, MPD5 elicited IgG antibody responses in a subset of PV patients who had benefited from a variety of therapies-including IFN-a, Hydroxyurea, Imatinib mesylate, Anagrelide, and phlebotomy-but not in untreated PV patients or healthy donors, suggesting that MPD5 is a PV-associated, therapy-related antigen. In the granulocytes of PV patients who are responsive to therapy, up regulated MPD5 expression may serve to enhance immune responses. These findings provide new insight into the mechanism underlying regulation of the self-antigen repertoire that elicits anti-tumor immune responses in patients with myeloproliferative diseases, indicating the potential of these self-antigens as targets of novel immunotherapy.
Interferon-a (lFN-a) therapy induces remission of polycythemia vera (PV) (I), a myeloproliferative disease (MPD) (2) , suggesting that the antiself-antigen immunity plays an important role in controlling the disease due to autoimmunity promoting effect of IFN-a. However, the selfantigens eliciting an anti-PV immunity remained . poorly defined (3) . By applying SEREX (serological analysis of tumor antigens by screening cDNA library with patients' sera) to detect antigens that elicit immunity contributed to remission of MPDs (4), we have identified three broadly immunogenic antigens, CML66 (5) , CML28 (6-7) and MPD6 (3) . Most of these tumor antigens identified to date are conventional antigens-encoded by genes with genomic exon-intron organization. In contrast, some tumor antigens are unconventional cryptic antigens (i.e., encoded by introns of genes or the untranslated regions [UTRs] of mRNAs) that can elicit T cell responses (8) . However, it was not completely clear z.XIONG ET AL. whether unconventional antigens elicit humoral antitumor immune responses (3) .
Screening testis cDNA library with SEREX is a useful approach to identify aberrantiy expressed antigens based on the rationale that testis, an immune-privileged site, does not normally present its self-antigens to the immune system (8) . In this report we have identified-for the first time-a novel unconventional SEREX antigen, MPD5, that specifically reacted to serum samples from three PV patients who experienced IFN-a or other therapeuticinduced remission.
MATERIALS AND METHODS

Serum samples
In accordance with pre-approved IRB protocols and guidelines at Temple University, New York-Presbyterian Hospital and Baylor College of Medicine (BCM), serum samples were obtained from healthy donors, PV patients whose disease had undergone remission in response to IFN-a or other therapies, and untreated PV patients. Specifically, at BCM, we enrolled: 8 PV patients receiving IFN-a treatment and 10 PV patients receiving other treatments; at New York-Presbyterian Hospital, we enrolled: 12 PV patients receiving IFN-a treatment, 24 PV patients receiving other treatments and 6 PV patients who had not yet received any treatment. The therapeutic regimens other than IFN-a for the 34 patients with PV included imatinib mesylate ( 16 patients), hydroxyurea (12 patients), hydroxyurea plus Anagrelide (three patients), Anagrelide plus phlebotomy (one patient), phlebotomy (one patient), and thalidomide (one patient).
Human testis cDNA library screening by SEREX
The library screening and DNA sequencing were performed, as previously described (3).
In vitro transcription and translation (TN])
TNT with plasmid containing MPD5 cDNA and a control were performed as reported (9) .
Bioinformatic analyses
Sequence analyses were performed in the NCBI/NIH website as reported (3, 10) .
Northern blot and Southern blot
Multiple tissue Northern blots (Ambion, Inc., Austin, TX) were hybridized with probes of the MPD5, NEK6 intron I region (outside MPD5) ( Fig. IA) , as reported previously (5) . The specificity ofthe NEK6 intron I region probe was confirmed by Southern blot hybridization of the NEK6 intron I fragment, as previously described (9) .
Semi-quantitative reverse transcription (RT)-PCR and PCR cloning
Human IFN-a (I x 10 5 units/IOO,uI) was purchased from PBL Biomedical Laboratories (Piscataway, NJ). Stimulation of K562 cells, a human myeloid leukemia cell line, with IFN-a was executed (1000 units/ml) for the indicated time points (II). RT-PCR and PCR cloning were performed, as described (9) . A sense primer (P V lOR F5) specific to the 5' sequence of MPD5 (5'-AACAGCAGCCCTTTCTCTCCA GTA-3') and an antisense primer (PVIORF3) (5'-TAATACGCAGCAGAGCTGGATTG-3') specific to the 3' sequence of MPD5 were used for PCR. The PCR products (290 bp) were cloned into pCRII-TOPO vector (Invitrogen). As a control, PCRs were performed for fJactin with a sense primer, HB-actin5 (5'-ATCTGG C ACCACACCTTCTACAATGAGCTGCG-3'), and an antisense primer, HB-actin3 (5'-CGTCATACTCC TGCTTGCTGATCCACATCTGC-3'). The signals of PCR products were normalized as relative densitometric units via comparison to fJ-actin signals amplified in the same cDNA preparations (9) . PCR for the amplification of ISGI5 was performed with a sense primer, ISG5 (5'-GAGAGGCAGCGAATTCATCT-3'), and an antisense primer, ISG3 (5'-AA GGGGGACCCTGTCCTG-3'), as a positive control for the genes upregulated by IFN-a stimulation, as reported (II).
Quantitative RT-PCR
Quantitative RT-PCR-used to determine MPD5 mRNA in total RNA isolated from peripheral blood granulocytes via TaqMan One-Step RT-PCR Master Mix Reagents (Applied Biosystems, AB, Foster City, CA)-was performed on the ABI PRISM 7000 System (AB) (3). The primers and TaqMan probe for MPD5 were synthesized by AB, including: MPD5-EX IF (forward primer), 5'GCTGAGATTGCGCCACTGT A3'; MPD5-EXIR (reverse primer), 5'CCTCTCCT AGGCTCCAAGTGT3'; and MPD5-EXIMI (probe labeled with FAM), 5'TCCAGCCTGGGATTC3'. Used as the reference standard and labeled with VIC f1uorophore (targeted center of sequence: 606 bp), the 18S ribosomal RNA were also purchased from AB. The amount of RNA representing the linear range of response for MPD5 and 18S was employed (i.e., typically, 100 ng -0.01 ng RNA/reaction). PCR without RT was also executed for control. Threshold cycles (CT) at the reporter signal were normalized with the reference gene, 18S (h 18S), and L1CT [L1CT = CTx -CT R' the difference in threshold cycles for the target gene X and the reference (R)] was calculated (2) . Mean JCT was compared among groups via ANOVA (12) .
Peptide synthesis and peptide ELISA
An MPD5-specific peptide was synthesized according to the sequence of MPD5, from aa 30 to aa 47 (N-TLNLSTGQASSPQCLLPS-C), at Sigma-Genosys (The Woodlands, TX). ELISAs were performed, as previously described (5) .
Transcriptional clonality assay
The genotypes for exonic polymorphisms of 5 Xchromosome genes (i.e., MPPl, IDS, G6PD, BTK, and FHLl) ofthree PV patients were determined (2) .
RESULTS
A novel PV-associated SEREX antigen, MPD5, is an unconventional antigen
SEREX screening of human testis expression cDNA library was performed using diluted sera collected from 3 PV patients who responded to IFNa therapy; these patients were selected, based on two criteria: (1) the patients' diseases had undergone remission, as judged by conversion from monoclonal to polyclonal hematopoiesis (2) (not shown); and (2) improved blood counts (1) (2) . A screening of 1x 10 6 A phage clones led to the identification of two identical clones.
The open reading frame (0RF) in the clone (1517 bp) encoded 47 amino acids with the molecular size of 5 kD, herein referred to as MPD5 (GenBank accession: AY567967). The antisense sequence of MPD5 was identical to a 5.1 kb cDNA clone (GenBank accession: AL832574; not shown). Both MPD5 and the 5.1 kb clone were located in intron 1 of NEK6 (i.e., NIMA [never in mitosis gene a]-related kinase 6) (GenBank accession: NT_008470.16). A member of the serine/threonine kinase family, NEK6 is a homolog of histone H3 kinase, which is required for cell cycle progression through mitosis (13) . The 5.1 kb cDNA was encoded on the same strand as the sense-strand of the NEK6 gene; whereas, MPD5 was encoded in the complementary strand within the intron 1 region of the NEK6 gene ( Fig. lA) .
Notably, there were no long ORFs found in the sense and complementary sequences of this 5.1 kb cDNA clone. The function of the 5.1 kb cDNA is unclear; however, our identification of the MPD5 and 5.1 kb clones in the cDNA library suggest that the region in intron 1 of NEK6 is transcriptionally active on both strands. This argument is further supported by our in silico analysis on the promoter regions for MPD5 transcription, which showed several transcription factors including interferon regulatory factor-l (IRF-l) binding sites (14) and sites for NF-KB (15) , c-fos, and AP-l (Fig. IB) .
The 5kD ORF of MPD5 was confirmed by TNT, depicted in Fig. 1C . The MPD5 protein sequence ( Fig. 1D) was not identical to sequences in the NCBI databases or the SEREX database (http:// www2.licr.orgiCancerImmunomeDB/), although a segment in the 3'untranslated region of MPD5 showed homology to a SEREX clone HOM-HD2-117 (the SEREX database, not shown). The following features support our contention that MPD5 is a human protein ( Fig. 1D ): 1) the start codon and the surrounding sequence contain the Kozak consensus for optimal translation (16); 2) the frequencies of amino acid (a.a.) codon usage, including a.a. residues with multiple codons, are identical to those used in human proteins; 3) analysis using the NCBI conserved domain database demonstrates that the a.a. sequence of MPD5-specifically, aa 7 to aa 43-has a high homology (i.e. 49%) with the GTPase Dblhomologous (DH) domain (Protein family database: http://pfam.wust1.edu/, pfam00621); and (4) the MPD5 sequence encoded several sites from various posttranslational modifications, including cyclin interaction, protein kinase A phosphorylation site, and N-glycosylation site. Cumulatively, these MPD5 features correspond to the characteristics previously reported in short protein-encoding ORFs (17) . Furthermore, in the Kyte-Doolittle hydrophilicity plot of the MPD5 peptide (Fig. 1E) , the two hydrophilic regions suggest the potential for antibody binding epitopes (10) .
The expression of MPD5 transcripts is elevated in tumors and PV
Applying our reported strategy (5) (6) , the Northern blot shows that the expression of MPD5 in 10 normal tissues (e.g., the brain [Nl], colon [N5], prostate [N8], testes [N9], and ovary [NIO], etc.) was negligible ( Fig. 2A) . However, MPD5 expression was significantly upregulated in a variety of tumor cells ( Fig. 2B) , including acute T cell leukemia (Tl), Burkitt's lymphoma (T2, T4, and T7), uterine carcinoma (T6), osteosarcoma (T8), histiocytic lymphoma (T9), and cervical adenocarcinoma (TIO). Since the MPD5 is located on the antisense strand of intron I within the NEK6 gene (Fig. IA) , the Northern hybridization signals in tumor tissues ( Fig. 2B ) resulting from hybridization might have been attributable to contaminated genomic DNA in the RNA preparation. In order to exclude this possibility, we generated a 3.6 kb NEK6 intron I (intron I) region (the lower panel in Fig.   2B ) that has no overlap with the MPD5 region ( Fig.  IA) . Hybridization of the Northern blot with the intron I probe did not yield any observable signals, suggesting that the MPD5 signals ( Fig. 2B ) did not result from contaminated genomic DNA. In contrast, the Southern blot hybridization on agarose gel-used to analyze the intron I fragment with a special intron I probe-showed a strong signal (lower panel, Fig.  2B ). This suggests that the intron I probe is capable of detecting potentially contaminated genomic DNA in tumor tissue RNA preparations (Fig. 2B ). To summarize, our findings indicate the detection of upregulated MPD5 expression in tumor cells. We subsequently examined MPD5 expression in granulocytes via quantitative PCR, with 18S as the normalizer (2), to calculate MPD5 expression levels in PV patients receiving IFN-a therapy (n= 10), PV patients receiving other treatments (Hydroxyurea, Imatinib mesylate, Anagrelide, or Phlebotomy; n= 16), PV patients receiving no treatment (n=6), and healthy donors (n=12). Of note, as previously reported (2), low JCT values indicate higher expression of a specific gene. As shown in Fig. 2C, MPD5 was not expressed in the granulocytes of healthy donors (mean ± 2 x standard deviations [2SD] of the JCT [MPD5-18S] = 28.5 -31.5). Conversely, MPD5 expression levels in the granulocytes ofPV patients receiving IFN-a (mean ± 2SD oftheJCT [MPD5-18S] = 24 -27) and those of PV patients receiving other treatments (mean ± 2SD of the J CT [MPD5-18S] = 25 -27.5) were higher than those ofuntreated PV patients or healthy donors (mean ± 2SD of the J CT [MPD5-18S] = 28.5 -31.5) (p<0.05). Notwithstanding, MPD5 expression levels in the granulocytes of PV patients receiving IFN-a were not higher than those of patients receiving other treatments (p>0.05). It is also noteworthy that the discrepancy between the numbers of patients and healthy controls in Fig. 2C and that in Fig. 3 resulted from the limited volumes of some blood samples, in which high quality RNAs could not be prepared. but the sera could be prepared for performing the experiments presented in Fig. 3 . We further hypothesized that MP05 expression in tumors can be upregulated either by direct IFNa stimulation associated with IFN-a therapy or, potentially, through the activation of IRF-1 using other therapies (14) . This hypothesis was supported Fig. 3 . MPD5 peptide specifically reacts to sera from PV patients responding to therapies. IgG antibody responses to the C-terminal antigenic epitope (from aa 30 to aa 47) of MPD5 Were detected by peptide ELISA. These experiments were repeated three times, and representative results are shown. The mean plus three standard deviations (SD) of the OD405 peptide ratios over the coating control (derivedfrom 23 healthy donors) was calculated as the upper limit ofthe normal range of MPD5 peptide antibody responses (the mean + 3SD = 1.38). The groups with detection rates of IgG antibody responses to MPD5 peptide that are statistically higher than those ofhealthy donors (the chi-square goodness-of .fit test; p<0.05) are marked with an *. by our in silico mapping of IRF-1 binding sites (G(A)AAAG/CT/CGAAAG/CT/C) (14) in the MP05 promoter region (Fig. IB) . In Fig. 20 , the results of semi-quantitative RT-PCR showed that MP05 transcripts in K562 myeloid leukemia cells were upregulated by IFN-a stimulation, even though the upregulation scale (nearly 100%) of MP05 was not as high as that (200%) of IFN-a-stimulated gene-15 (ISG 15) ( Fig. 20) , which was employed as a positive control for the IFN-a-stimulated genes (II). Of note, the amplification of MP05 transcripts by RT-PCR did not result from genomic DNA potentially contaminated in RNA prepared from stimulated K562 cells; this conclusion is based on the following: (1) the RNA were treated with RNase-Free DNase before reverse transcription and (2) the PCR involving primers located in the NEK6 intron I region outside of MP05 did not result in any amplified products. However, the results suggest that a transcriptional mechanism in K562 cells could be one of the regulatory programs implicated in the upregulation ofMP05 expression induced by IFN-a or IRF-I activation associated with other therapies (14) . The limited number of PV patients prevented similar IFN-a stimulation performed with PV cells.
MPD5 peptide specifically reacts to sera from PV patients who experienced therapeutic-induced remission, but not sera from untreated patients or healthy donors
To further verify whether MP05 antigen epitope is immunogenic in vivo, an MP05 peptide was synthesized according to the amino acid sequence of the second antigen epitope of MP05, from aa 30 to aa 47 (Figs. 10 and E). MP05 peptide-specific IgG antibody responses, shown as the 00405 ratio (00405 MP05 peptide/00405 coating control) ( Fig. 3) , as we previously reported (18) , were negligible in the serum samples of all 23 healthy donors [the mean + 3S0 = 1.38]. Thus, in Fig.   3 , an 00405 ratio higher than 1.38 is considered positive for anti-MP05 IgG antibody responses. As summarized in Fig. 3 , MP05 epitope-specific IgG antibody responses were detected in serum samples from 5 out of 20 (25%) PV patients receiving IFNa therapy, and in 7 out of 34 serum samples (21%) from PV patients receiving other therapies ( Fig.  3) . Of note, a good correlation existed between o o increased MPD5 expression in granulocytes, as detected by quantitative PCR, and the specific antibody responses detected by ELISA in PV patients receiving IFN-a and other therapies. These results suggest that the antigenic epitope in MPD5 protein, which is naturally translated, was immunogenic in the PV patients receiving therapy. It is noteworthy that serum results obtained with the MPD5 ELISA corresponded well with those achieved through the phage plaque assay (not shown).
DISCUSSION
To the best of our knowledge, the identification of novel unconventional antigen MPD5 is a part of the first such study in PV and other BCR-ABL negative MPDs (3, (19) (20) . Prior to the current report, whether unconventional cryptic antigens (21) can elicit humoral immune responses has not been well defined. Our recent results on T cell antigen epitope of CML66 (22) indicate that integrated humoral and T cell immune responses to SEREX antigens are truly tumor-specific. The results of our analysis employing the methods (10) suggest that protein sequences of MPD5 have a high potential to encode T cell antigen epitopes. Several new systems contribute to protein antigen presentation and co-stimulation, and shape the T cell responses including Qa-l (23) and ICOS-B7RP-l (24) . The question of whether these new systems participate in elicitation of T cell responses to unconventional protein antigens, such as MPD5, remains unknown.
We demonstrated that upregulation of untolerized antigen structure via alternative splicing is a novel mechanism in generating the immunogenicity oftumor antigens (8, 18) . The current study on MPD5 suggests that overexpression of "intron antigens" in tumor cells is one ofthe mechanisms involved in eliciting immune responses. In addition, overexpressed antigens must have untolerized antigen epitopes partially by splicing (25) . Furthermore, overexpressed antigens must access the antigen presentation pathway and immune system by the following mechansms (3): 1) releasing from damaged tumor cells followed by crosspresentation; 2) translocating across the intracellular membranes and entering exosome for the MHC class II antigen presentation pathway. Notwithstanding, the correlation between antigen-specific IgG immune responses and remission in PV patients (I) indicates that immune responses mediated by unconventional antigen(s) may contribute to MPD remission (5) (6) 8) .
